University Adopts CardioQ

Deltex Medical Group PLC
12 May 2005


                              Deltex Medical Group plc

 Radboud University Nijmegen Medical Centre adopts CardioQTM as a standard of
                                      care


12 May 2005: Deltex Medical Group plc ('Deltex Medical' or the 'Company'), the
AIM listed haemodynamic monitoring company, today announces that Radboud
University Nijmegen Medical Centre has become the first major university
teaching hospital in Europe to adopt its CardioQ cardiac function monitor as a
standard of care in hospitals around the world.

Following a six-month period of evaluation in both adults and children
undergoing surgery, the hospital has entered into a contract with the Company's
distributor in the Netherlands, MTT, to install six CardioQ monitors and two
CardioQPTM dedicated paediatric monitors. The contract specifies a target usage
of up to 80 probes per month in this first phase of implementation.

Andy Hill, Deltex Medical's Chief Executive, commented:  'The adoption of our
products as part of routine surgical care at Radboud University Nijmegen Medical
Centre is a significant step forward in our goal to make haemodynamic
optimisation a standard of care across Europe and the rest of the world.

'In the Netherlands, like much of the rest of Europe and in the US, patients
benefit from a far higher level of post-operative care provision than in the UK.
Nevertheless, doctors in Nijmegen have satisfied themselves that using the
CardioQ can deliver significant clinical benefits and offers real opportunities
for improving efficiency and cost-effectiveness of care delivery.'



For further information, please contact:-


Deltex Medical Group plc                                           01243 774 837
Nigel Keen, Chairman
Andy Hill, Chief Executive
Ewan Phillips, Finance Director

Financial Dynamics
David Yates                                                        0207 831 3113
Lucy Briggs



Notes for Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs.  This causes medical
complications including peripheral and major organ failure which can lead to
death.  Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself.  Using fluids and drugs, guided by the CardioQ, to optimise the amount
of circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-

  • validated the results of the Monitor against known standards for measuring
    cardiac output, demonstrating that the technology works

  • proved that the CardioQ works in a wide range of surgical procedures

  • demonstrated that the Company's technology provides significant health and
    economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.


                      This information is provided by RNS
            The company news service from the London Stock Exchange